论文部分内容阅读
目的:观察凯时治疗糖尿病周围神经病变的临床疗效。方法:对确诊为糖尿病合并周围神经病变的69例患者随机分为治疗组和对照组两组。治疗组35例给予Lipo-PGE1治疗,10μg/d,共两周;对照组34例,给予维生素B110 mg/d、维生素B12500μg/d治疗,共两周,对其疗效进行比较。结果:治疗组用Lipo-PGE1治疗两周后,患者自觉症状和体征有明显改善,与对照组比较有显著性差异(P<0.01)。尺神经和腓神经MNCV及SNCV,治疗组前后比较有明显增加(P<0.01),对照组治疗前后比较有增加(P<0.05),治疗组与对照组比较明显增加(P<0.01),均有显著性意义。治疗组治疗过程中未出现严重副反应。结论:Lipo-PGE1是治疗糖尿病周围神经病变有效且安全的药物。
Objective: To observe the clinical effect of treatment of diabetes mellitus peripheral neuropathy. Methods: 69 patients diagnosed with diabetes mellitus and peripheral neuropathy were randomly divided into treatment group and control group. In the treatment group, 35 cases were treated with Lipo-PGE1, 10μg / d for two weeks. In the control group, 34 cases were given vitamin B110mg / d and vitamin B12500μg / d for two weeks. The curative effect was compared. Results: After treatment with Lipo-PGE1 for two weeks, the symptoms and signs of patients in the treatment group were significantly improved (P <0.01) compared with the control group. The number of ulnar nerve and peroneal nerve MNCV and SNCV in the treatment group were significantly increased before and after treatment (P <0.01), compared with the control group before and after treatment (P <0.05), the treatment group and the control group were significantly increased (P <0.01) Have significant significance. The treatment group did not appear during the treatment of serious side effects. Conclusion: Lipo-PGE1 is an effective and safe drug for the treatment of diabetic peripheral neuropathy.